Adaptimmune Therapeutics PLC at JPMorgan Healthcare Conference Transcript
&-
Morning, and thank you for coming. My name is Jem de los Santos. I work in the investment banking practice at JPM based in London. Very pleased today to present Adrian Rawcliffe of Adaptimmune.
Thanks, Jem, and thank you, everybody, for joining us. I'm Rawcliffe from the CEO of Adaptimmune, and I'm absolutely delighted to be here at the beginning of 2024. Because 2024 will be the year where Adaptimmune transforms from merely the pioneering force in bringing cell therapies for solid tumors into an integrated commercial cell therapy company, through the approval and launch of Afami-cel, the first engineered T-cell therapy for the treatment of solid tumors and the start of a sarcoma franchise that we believe will be highly valuable and a beachhead for getting cell therapies into the solid tumor space and becoming mainstream in that space.
This is the disclaimer which will cover the forward-looking statements. I plan on making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
